BIGBEAR Pharmaceutical announces the approval of Adagrasib in Laos

Adagrasib, a KRAS ^G12C inhibitor, irreversibly and selectively binds KRAS ^G12C, locking it in its inactive state. Similar to sotorasib, adagrasib is a selective covalent inhibitor of KRASG12C; however, reported pharmacologic differences in the molecules are the drug half-life of 5 hours for sotorasib as compared with 23 hours for adagrasib, dose-dependent extended exposure with adagrasib, and potential CNS penetration of adagrasib.

Adagrasib is a prescription medicine used to treat KRAS G12C–mutated ocally advanced or metastatic non–small cell lung cancer (NSCLC) or metastatic colorectal cancer (CRC)